(Q82397762)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

demyelinating polyneuropathy

16 January 2020

main subject

1 reference

E A Marsh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C L Hirst

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J G Llewelyn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M D Cossburn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M M Reilly

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A Krishnan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M Doran

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A M Ryan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A J Coles

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J L Jones

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

N P Robertson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

6 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

913-919

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20049473%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-009-5437-3

16 January 2020

exact match

0 references

cites work

Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system

1 reference

12 December 2020

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

1 reference

12 December 2020

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

12 December 2020

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

12 December 2020

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

1 reference

12 December 2020

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

1 reference

12 December 2020

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

1 reference

12 December 2020

Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

12 December 2020

Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

12 December 2020

Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy

1 reference

12 December 2020

Relapsing demyelinating disease affecting both the central and peripheral nervous systems

1 reference

12 December 2020

Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force

1 reference

12 December 2020

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

1 reference

12 December 2020

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

12 December 2020

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection

1 reference

12 December 2020

Mechanisms of immune regulation in the peripheral nervous system.

1 reference

12 December 2020

Central lesions in chronic inflammatory demyelinating polyneuropathy: an MRI study.

1 reference

12 December 2020

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

1 reference

12 December 2020

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.

1 reference

12 December 2020

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

12 December 2020

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

12 December 2020

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

12 December 2020

Management of inflammatory neuropathies

1 reference

12 December 2020

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

Campath-1H therapy in refractory ocular inflammatory disease

1 reference

12 December 2020

Side-effects of intravenous immune globulins

1 reference

12 December 2020

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

12 December 2020

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

1 reference

12 December 2020

Autoimmune responses in peripheral nerve

1 reference

12 December 2020

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H

1 reference

12 December 2020